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Abstract
To seek the best solvent in which the peptide can dissolve is 
usually a serious challenge in peptide chemical synthesis. Ionic 
liquids, which are liquid below 100 °C, or even at room 
temperature, showed an outstanding solubility for polar 
compounds, unpolar compounds and even biological 
macromolecules. Furthermore, ionic liquids are also recognized 
as a green solvent because of their special properties, 
such as non-flammability, thermal/chemical stability, no 
measurable vapor pressure and recyclability. Thus, ionic liquids 
have attracted increasing interest in the field of peptide synthesis. 
In this thesis, the compatibility of ionic liquids for the Native 
Chemical Ligation strategy at a X–Cys ligation site (X = any amino 
acid) was analyzed and compared to the conventional ligation 
strategy. Besides that, the initial attempts of lactam bridge 
formation of cyclic peptides in ionic liquid have been made with 
the aim to complete the insufficient knowledge regarding peptide 
cyclization in ionic liquids. In conclusion, this thesis obtains an 
impression on how the application of ionic liquids for both 
reaction types provides essential contributions to the field of 
peptide chemistry employing alternative reaction media.
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1. Introduction
1 
1 Introduction 
 A suitable dissolution method is an important factor for the success of 
peptide synthesis, especially the solution-phase peptide synthesis. An 
inadequate solvent can lead to precipitation and denaturation of the peptide of 
interest during the synthesis process, purification and also analysis. Peptides 
possess variable solubility properties, which are dictated by their amino acid 
composition, length of sequences and secondary structure. Although some 
peptides can be dissolved in aqueous solutions, organic solvents or mixtures 
of these, no conventional solvent has been found to be ideal for all kinds of 
synthetic peptides. Therefore, it is quite a challenge to find out the best solvent 
for distinct peptides. 
 A series of novel solvents, so-called “room temperature ionic liquids 
(RT-ILs)” (generally also “ionic liquids”, ILs) referred to as salts with a melting 
point under room temperature, has been introduced as potential alternatives to 
conventional organic solvents recently. ILs exhibit varying physical and 
chemical properties, such as low viscosity, negligible vapor pressure, 
non-flammability, high thermal and chemical stability.  Significantly, ILs have 
also good dissolubility for a wide range of polar as well as non-polar 
compounds and biological macromolecules, too.  Due to the outstanding 
features of ILs, several attempts have been made to use them in chemical 
peptide synthesis, however, these were primarily focused on solution synthesis 
for the generation of small peptides possessing less than four amino acids. 
The studies of peptide synthesis in ILs are thus still not comprehensive. 
Therefore, in the first part of this thesis the compatibility of the Native Chemical 
Ligation strategy for combining peptide fragments at a X–Cys ligation site (X = 
any amino acid) should be analyzed and compared to the conventional ligation 
strategy. In the second part, the initial attempts of lactam bridge formation of 
cyclic peptides in ILs should be investigated with the aim to complete the 
insufficient knowledge regarding peptide cyclization in ILs. Taken together, this 
thesis should give an impression on how the application of ILs for both reaction 
types provides essential contributions to the field of peptide chemistry 
employing alternative reaction media. 
2 State of Knowledge  
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2 State of Knowledge 
 Today, therapeutic compounds on the market are divided into two 
categories: low molecular weight compounds (small molecules) and large 
(bio)molecules (also biologics or biopharmaceuticals). 1  Classical small 
molecules have been extensively studied as drugs over the past decades. 
They can generally be manufactured easily and still dominate the 
pharmaceutical market today. Biologics are commonly limited to peptides and 
proteins, such as hormones, vaccines and antibodies. Mass production of 
peptides and proteins, however, is more challenging compared to small 
molecules (Table 2.1).1,2 Most biologics are unstable and require special 
storage and handling. Peptides and proteins can be degraded by ~600 
different proteases in vivo before they reach their target.3 Hence, there were 
only a handful of commercial biologics on the market until 20-30 years ago, 
including e.g. insulin, human growth hormone, hepatitis B vaccine, -interferon 
and tissue plasminogen activator (tPA).4 
Table 2.1 Characteristics of biological drugs compared to small molecule-based 
drugs.1,2 
 Small molecule-based drugs Biomacromolecule-based drugs 
Molar mass low (up to 500 g/mol) high (>> 500 g/mol) 
Structure Simple complex 
Modification well defined many options 
Analysis complete difficult, partially incomplete 
Manufacturing chemical synthesis, relatively 
simple and cheap 
isolation from natural sources, 
biochemical, biotechnological or 
chemical production, expensive 
and complicated 
Stability mostly stable often unstable, sensitive 
Immunogenicity mostly non-immunogenic possibly immunogenic 
2 State of Knowledge
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Historical data from the American Food and Drug Administration (FDA) 
revealed that high failure rates (>90%) of novel drug candidates in their clinical 
trials and the approval process result in exorbitant costs (Figure 2.1-B,C) and 
long cycle time of current drug development (Figure 2.1-A).59 However,
according to the market reports,6,9 biological drug candidates perform
with higher success rates than small molecules at all phases of 
development (Figure 2.1-A). More than 13% of large biomolecules have
been successfully approved by the FDA. This final pass rate is about twice 
that of small molecule drugs (approx. 7%). Thus, the large biomolecules 
have attracted increasing attention from global pharmaceutical companies.
Figure 2.1 (A) Overview of the drug development process (adaptation based on
resource5) and phase success rates by molecule size;6 (B) Historical trend of drug 
research and development spent (USA) from 1980 - 2014;7 (C) Historical trend of the 
average cost to develop one drug (USA) from 1970s - early 2010s.8,9
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The market report “2014 FDA Drug Approvals” 10 revealed that the 
proportion of approved biologics has obviously increased from 8% in 1993 to 
37% in 2014 (Figure 2.2-A). It needs to be highlighted that among biologics,
the peptide drugs have become the second largest category of approved drugs 
besides the small molecule drugs on the market in 2012 (Figure 2.2-B).11
 Peptides are defined as biomacromolecules composed of amino acid 
residues which are linked together via peptide bonds between their respective 
carboxyl and amino functional groups. The structural organization of peptides 
and proteins, however, differs in that peptides generally possess a greater 
flexibility and, in turn, different structural and functional roles compared to 
proteins, 12 though exceptions of highly structured and conformationally 
constrained peptides such as toxins stabilized by several disulfide bonds exist.
Peptides, which fill the molecular weight gap澳 between conventional small 
molecule drugs (<500 Da) and biologics (>5000 Da),13 have been approved in 
the treatment of various diseases, such as cancer, cardiovascular, and 
metabolic disease (Figure 2.2-C).14 Since the successful commercialization of 
the peptide hormone insulin in 1982, the number of patent applications for 
peptide drugs has raised significantly (Figure 2.2-D).15 More than 60 peptide 
drugs have reached the market and several hundreds of novel peptide 
candidates are now in preclinical and clinical trials.16 This can be exemplified 
with diagnostic reagent Ȗ-GT II (dipeptide glycylglycine used for diagnosis 
and/or prediction of osteoporosis),17 Prialt® (SNX-111 or ziconotide, 25mer 
peptide N-type calcium channel blocker)18 and Fuzeon® (enfuvirtide, 36mer 
antiretroviral peptide). 19 A market research from Japan 20 forecasts that,
compared to the statistics of 2012, the market of patented peptide drugs will 
grow up with a rate of 44% in 2020 and benefiting from a huge number of drug 
patent expirations in 2020, the market size of generic peptide drugs will then 
be tripled (Figure 2.2-E).20
2 State of Knowledge
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Figure 2.2 (A) Small molecule-based drugs and biologics license applications 
approved by the Center for Drug Evaluation and Research (CDER) since 1993 and 
the corresponding historical trend of approved biologics percentages;10 (B) Modality 
breakdown of novel drug approvals in 2012;11 (C) Global peptide drugs market 
revenue by therapeutic indications in 2014;14 (D) Historical trend in patent applications 
for therapeutic peptides from 1980 until 2012 (adaptation based on resource15); (E)
Forecasting of market shares for patented and generic peptide drugs.20
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2.1 Peptides as drugs
Compared to common small molecule drugs, peptide drugs have 
both, potential advantages and disadvantages.21 A primary reason for 
the increasing interest in peptides and small proteins is that they bind 
with exquisite specificity to their in vivo targets, resulting in 
exceptionally high potencies of action and relatively few off-target side 
effects.22 Peptides have been found to possess different beneficial
properties such as antimicrobial, anticancer, antioxidant, antithrombotic, anti-
hypertensive, mineral-binding, and immunomodulation.23,24 However,
applications of synthesized peptides have been severely limited by their 
low systemic stability, solubility problems, high clearance, poor membrane 
permeability, low oral bioavailability, and high production costs. Thus,
manufacturing of peptides is the largest bottleneck for the commercialization 
of many potential peptide drugs (Table 2.2).21
Table 2.2 Advantages and disadvantages of peptides as therapeutics (adaptation
based on resource21).
Disadvantages
High activity Low oral bioavailability
High specificity Injection required
Broad spectrum activity with few side effects Low systemic stability
Minimization of drug-drug interactions Difficult delivery, poor membrane permeability
Less accumulation in tissues and organs
Lower toxicity than small molecules Solubility challenges
Often potent High clearance
Biological and chemical diversity Immunogenic effect
$dvantages
2 State of Knowledge
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2.2 Chemical synthesis of peptides
Currently there are various primary technologies for peptide production, 
such as extraction from natural sources25, combinatorial biosynthesis26 and
chemical synthesis, available.27,15 Since it is relatively difficult to isolate and 
characterize natural peptides from the respective biological sources, many 
large peptides, such as insulin28, somatostatin29 and other hormones,30 have 
been produced through combinatorial biosynthesis. Compared to the 
biosynthesis of synthetic polypeptides, chemical synthesis is a feasible 
technology for the production of small and medium-sized peptides ranging 
from about 5 to 80 residues,31 especially for the synthesis of natural peptides 
which are difficult to express in bacteria, peptides containing unnatural amino 
acids or D-amino acids and peptide backbone modification (Table 2.3).
Table 2.3 Advantages and disadvantages of primary synthetic approaches to peptide 
production.15
Extraction from nature Combinatorial biosynthesis Chemical synthesis
Choice for selected natural 
peptides
Choice for production of long
polypeptides and proteins
Choice for production of 
short and long peptides
Limited sources of raw 
materials
Low cost of raw materials Relatively high cost of raw 
materials
Difficult purification Difficult purification Easier purification, higher
purity
Unstable yields Low yields Good yields, low yields for 
production of long peptides
Large batch production Large batch production Small batch production,
time-consuming
Safe Safe and clean Possibly toxic reagents
2 State of Knowledge
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2.2.1 Overview of available methods
 Chemical peptide synthesis is commonly considered as the formation of 
peptide bonds which link amino acid residues together between their 
respective carboxyl (N-terminal amino acid) and amino (C-terminal amino acid) 
groups. The history of technologies developed for chemical peptide synthesis
dates back to more than 100 years ago,32 and they are still widely used in 
peptide production so far. Chemical peptide synthesis can be divided into solid 
phase synthesis and solution phase synthesis. 
In 1963, Robert Bruce Merrifield pioneered solid-phase peptide synthesis 
(SPPS),27 which consists of repeated cyclic processes resulting in the 
elongation of a peptide chain anchored to an insoluble resinous polymer by 
successive couplings of amino acids until the desired peptide sequence is 
assembled completely (Scheme 2.1).33 Protecting groups are required to 
temporarily shield the Į-amino group and side-chain functionalities of amino 
acids in SPPS method, so as to avoid polymerization of amino acid excesses 
used to ensure complete coupling. Two most common types of protecting 
groups are the N-tert-butyloxycarbonyl (Boc) 34 and fluorenyl-9-methyloxy- 
carbonyl (Fmoc),35 which can be easily cleaved. It is generally considered that 
the length limitation of peptides prepared by SPPS is approximately 50 amino 
acid residues (limit may fluctuate depending on individual peptide sequence) in 
order to obtain a satisfying yield of final product. Even though 66mer,36
95mer 37 or even longer polypeptides 38 have been reported to be also 
synthesized by SPPS method, the overall yields of these peptides are still
relatively low or unstable. 
6WDWHRI.QRZOHGJH
濌澳
6FKHPH  $ IORZ GLDJUDP RI VROLG SKDVH SHSWLGH V\QWKHVLV 6336 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EDVHGRQUHVRXUFH
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There are two types of solution phase synthetic approach: stepwise 
assembly and fragment assembly.39.40 The stepwise assembly of peptides in 
solutions, which is usually regarded as an “old” or “classical” peptide synthesis
method, has been replaced by mature SPPS technology in most cases. In
general, the side chains of peptide fragments should also be protected during 
each synthesis step. In the method of stepwise assembly, coupling reactions
between amino acids are carried out in solution instead of the polymer support
used in SPPS. The classical stepwise assembly method is still valuable for the 
synthesis of small peptides like dipeptides, tripeptides, for some large-scale 
manufacturing and for specialized laboratory applications today.41
The second approach is the fragment assembly. The concept is to connect 
the synthesized peptide fragments via amide (peptide) or other chemical 
bonds,42 e.g. peptide thioester43 or thiazolidine ester.44 Long peptide chains
can be formed by the coupling of small protected or even unprotected peptide 
fragments. Among them, several fragment ligation methods, which have been 
developed to make the ligation of unprotected peptide fragments possible, will 
be introduced in the next section. 
2 State of Knowledge
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2.2.2 Ligation of peptide fragments*
In the ligation methods, unprotected peptide segments can be coupled 
orthogonally to form long peptide chains or large proteins, usually in good yield 
(42-95% total yield) and of high purity.36,45,46 Because of their superior
advantages, these methods have been widely used in the synthesis of 
peptides and small proteins, such as cytochrome b562 (106 AAs),47
His-tagged interleukin-2 (133 AAs)48 and insulin lispro (51 AAs).49
The ligation methods were commonly divided into the ligation methods 
using imine and thioester capture strategies.42 The most frequently used 
ligation methods for peptide synthesis have been summarized in Table 2.4,51
and individual approaches of these methods are further illustrated in details as 
for example thioester ligation (Scheme 2.2), thioether ligation (Scheme 2.3-A)
and imine ligation (Scheme 2.3-B,C,D,E,F), respectively.51 Since no natural 
amino acid residue can be obtained at the ligation site in case of the imine and 
thioether ligation methods, thioester-based ligation is by far the more 
commonly used method in peptide synthesis.
The first thioester ligation, in which an amide bond was formed upon the 
reaction of valine-S激phenylalanine with cysteine, was observed by Theodor 
Wieland and coworkers already in 1953.50 The reaction mechanism of a 
thioester-based ligation is a procedure involving two elementary steps. In the 
initial step, an intermediate, such as a covalent thioester or perthioester, is 
formed by two segments with the functionalities of a thioester or its analogues 
and a thiol nucleophile. This step is usually reversible. After a rapid S-N acyl 
rearrangement step, the thiol bond of the intermediate is transformed into an 
amide bond spontaneously and irreversibly. After about 40 years, various 
ligation technologies, such as cysteine, selenocysteine, methionine, glycine 
and histidine ligations have been developed based on the thioester-based 
* The full text of this capture was modified from the author’s publication51
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method for producing unprotected peptides. Among them, the cysteine ligation 
has become the most popular and convenient method for chemoselective 
synthesis of polypeptides and proteins. 
Table 2.4 Imine and thioester capture strategies for ligation methods (adapted with 
permission from the author’s publication51). 
Method Segment Product Examplea Ref.a
Cysteine and 
selenocysteine ligation
1 + 2 3 Human interleukin 8 
(IL-8)
1994
Methionine ligation 1 + 4 5 Parathyroid hormones 1998
Glycine ligation with 
N-linked auxiliary thiols
1 + 6 7 Gly12-brain natriuretic 
peptide5–26, porcine
2007
Histidine ligation 9 + 10 11 - -
Cysteine-aziridine ligation 12 + 13 3 - - 
Cysteine-bromoalanine 
ligation
12 + 14 3 - -
Cysteine-perthioester 
ligation
12 + 15 16 K48-linked diubiquitin 2010
Thioether ligation 12 + 18, 19 20, 21 HIV-1 protease 1992
Pseudoproline ligation 22 + 23 24 Model 50-residue 
peptide
1994
Oxime and hydrazine 
ligation
26 + 27 28 - -
Thiazolidine ligation 26 + 2 29 - -
Tetrahydro-E-carboline 
ligation
30 + 31 32 - - 
Ketoacid–hydroxylamine 
ligation
33 + 34, 35 36, 37 - - 
a Selection is based on a peptide length larger than 20 amino acids. 
2 State of Know
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Scheme 2.2 (A) Cysteine and selenocysteine ligation; (B) Methionine ligation; (C) Glycine ligation with N-linked auxiliary thiols; 
(D) Histidine ligation; (E) Cysteine-aziridine; (F) Cysteine-bromoalanine ligation; (G) Cysteine-perthioester ligation (reprinted 
with permission from the author’s publication51).
2 State of Know
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Scheme 2.3 (A) Thioether ligation; (B) Pseudoproline ligation; (C) Oxime and hydrazine ligation; (D) Thiazolidine ligation; (E) 
Tetrahydro-E-carboline ligation; (F) Ketoacid-hydroxylamine (reprinted with permission from the author’s publication51).
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In 1994, a cysteine ligation method for peptide synthesis, the so-called 
“Native Chemical Ligation” (NCL), was introduced by Stephen Kent’s
laboratory.52 In NCL method, a long peptide containing cysteine can be formed 
directly by an unprotected peptide-Į-carboxy thioester and an unprotected 
peptide segment with an N-terminal cysteine residue. Just like the introduced 
mechanism of other thiol-based ligations, these two peptide segments first
combine with each other via reversible transthioesterification and a 
subsequent irreversible S-N acyl shift giving a “native” peptide bond as well as 
a cysteine residue at the ligation site (Scheme 2.4).52
In order to carry out an NCL reaction, the conditions of neutral pH (pH 6.5 
to 7.5) and aqueous phosphate buffer containing a chaotrope, e.g. guanidine 
hydrochloride or urea are generally necessary.52,53 Moreover, the addition of 
thiol additive(s), such as benzyl mercaptan, thiophenol and 4-mercaptophenyl 
acetic acid (MPAA), are also required to keep the cysteine side chains in a 
reduced state and to accelerate the initial transthioesterification step
(Scheme 2.4).53,54
The NCL method, which can overcome the length limitation of peptide 
synthesis occurring for the SPPS method, has become an efficacious
technology for the synthesis of polypeptides and proteins of a size ranging
from 50 to approximately 150 amino acids, such as the recently 
reported pore-forming antimicrobial protein caenopore-5 (82
AAs),55 the sialic-acid-binding lectin siglec-7 (127 AAs),56 human
interleukin-6 glycoprotein (183 AAs)57 and polydiscamides B, C, D from the 
sponge Ircinia sp. (13 AAs).58
濄濈澳
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Scheme 2.4 General mechanism of Native Chemical Ligation.53
The recent reports5961 showed that the type of the residue on the C-
terminus of the thioester segment could strongly influence the yield ofproduct
in NCL. Hackeng, T. M. et al. found that the ligation at a -Pro-Cys- site is
relatively difficult to be performed if applying NCL.60 The formation of a high
level of ȕ- and Ȗ-linked byproducts have been also found in native ligation at
-Glu-Cys- and -Asp-Cys- sites by using classical additives like thiophenol,59
whereas the E- and Ȗ-isomer formation occurring at the “-Glu-Cys-” site could
be prevented by utilizing the additive 4-mercaptophenylacetic acid (MPAA).61
However, MPAA has no advantage regarding the avoidance of the formation of
E-linked byproduct in the ligation reaction at the “-Asp-Cys-” site.61澳 Recent
improvements from Nakamura et al. revealed that increasing the concentration
of MPAA and the reaction temperature could facilitate the reaction rates of
peptide ligation.62
濄濉澳
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2.2.3 Preparation of cyclic peptides 
 The applications of linear peptides as pharmaceuticals or therapeutic 
agents are limited because of their poor cell permeability and in vivo 
instability.63 In contrast to linear peptides, cyclic peptides or cyclic peptide 
analogues have higher resistance to the degradation by exo- and endo- 
proteases.64 Since the first discovery of the cyclic peptide gramicidin S in the 
1940s, 65  cyclic peptides found exhibited a wide spectrum of biological 
activities and behaved as potential lead compounds of hormones, 66 
antibiotics, 67  ionophores, 68  antifungals, 69  and anticancer drugs. 70  Their 
application scope has been also expanded to the fields of therapeutic 
agents,71 nanomaterials,72,73 and supramolecular self-assembly.74 It is worth 
noting that disparate biochemical functions could be realized by fine-tuning of 
the cyclic peptide conformations using the techniques of chemical synthesis.64 
However, until now, it is still a difficult challenge to prepare cyclic peptides by 
using common synthetic methods.31 
 In theory, peptide macrocycles can be closed also by the similar strategies 
used for linear peptide assembly, while in most cases the peptide cyclization 
has to face the following actual problems. For small-to-medium-sized rings, the 
ground-state E geometry of the peptide bond causes supernumerary high 
angle strain of ring-shape conformation, which prevents the formation of the 
cyclized peptide. For larger rings, reaction conditions need to be carefully 
controlled to avoid the unwanted intermolecular combination between peptide 
molecules.64 
 Just like the ligation methods for linear peptides, there is a great variety of 
cyclization methods available. Among them, the most popular macrocyclization 
methods are lactamization, lactonization and disulfide bond formation. 
Depending on the site of cyclization, the four commonly used methods are the 
most frequently used: head-to-tail, head-to-side-chain, side-chain-to-tail and 
side-chain-to-side-chain (Scheme 2.5).64 Currently, the most common
2 State of Knowledge 
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cyclization methods of peptides are head-to-tail via a lactam bridge and 
side-chain-to-side-chain via a disulfide bond.64,75 
Scheme 2.5 General synthetic considerations for peptide cyclization (adaptation 
based on resource 64). 
 Peptide cyclization with formation of one or more disulfide bridges is 
usually observed in folding of the peptides bearing cysteine residues. Cysteine 
can be easily oxidized on air in solution to form a dimer called cystine. In 
contrast to the formation of disulfide bridges, head-to-tail cyclization via a 
lactam bridge usually requires relatively complex and special conditions. 
Cyclization is suggested to be performed under high dilution (10−3-10−4 M) 
conditions so as to protect against dimerization and oligomerization.75 
Furthermore, it is critical to choose a suitable coupling reagent for an effective 
head-to-tail cyclization reactions (Table 2.5).75 There are two sorts of coupling 
reagents, which have been frequently used in cyclization (Table 2.5).75,76 The 
first are the phosphonium derivatives of reagents such as PyBOP and PyAOP 
which have been used as efficient coupling reagents in solution-phase 
cyclization of e.g. pentapeptides with good yields (52-56%).77 The other kind 
are so-called uronium derivatives, such as HBTU and HATU, which are 
well-known as coupling reagents for solid-phase cyclization. In general, no 
excess of uronium salts is required in cyclization (1 equiv. of coupling reagent 
in the presence of 2 equiv. of tertiary base).78 In addition, the solubility of the 
2 State of Knowledge 
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cyclic peptides in conventional solvents is another challenge during synthesis. 
It has been reported recently that the three-dimensional conformational 
change in cyclic peptides can be induced by different reaction media.79 
Table 2.5 Recent popular coupling reagents for peptide cyclization via lactam bridge 
formation (adaptation based on resource75). 
Phosphonium derivatives Uronium derivatives 
1-benzotriazole-tris-dimethylaminophospho
nium hexafluorophosphate (BOP)
O-(benzotriazol-1-yl)-1,1,3,3 tetramethyl 
uronium hexafluorophosphate (HBTU) 
1-benzotriazolyloxy-tris-pyrrolidino
phosphonium hexafluorophosphate
(PyBOP)
O-(benzotriazol-1-yl)-1,1,3,3 tetramethyl 
uronium tetrafluoroborate (TBTU) 
7-azabenzotriazol-1-yloxy trispyrrolidino
phosphonium hexafluorophosphate
(PyAOP)
O-(7-azabenzotriazol-1-yl)-1,1,3,3 
tetramethyl uronium hexafluorophosphate 
(HATU) 
7-azabenzotriazol-1-yloxy-tris-dimethyl
aminophosphonium hexafluorophosphate
(AOP)
O-(7-azabenzotriazol-1-yl)-1,1,3,3 
tetramethylene uronium 
hexafluorophosphate (HAPyU) 
O-(7-azabenzotriazol-1-yl)-1,1,3,3 
pentamethylene uranium 
hexafluorophosphate (HAPipU) 
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2.3 Ionic liquids (ILs) as alternative reaction media 
 A series of novel solvents, so-called “room temperature ionic liquids, 
RT-ILs” (referred to as only “ionic liquids, ILs” in this thesis), which are salts 
with a melting point at room temperature, has been introduced as potential 
alternatives to conventional organic solvents quite recently. ILs have been 
evaluated as “green solvents”, 80  “solvents for the future” 81  or “designer 
solvents” 82  attracting increasing interest in the fields of electrochemistry, 
engineering, catalysis, physical chemistry, and organic chemistry.83 
 
2.3.1 Characteristic properties of ILs 
 ILs are usually comprised of organic cations associated with inorganic 
anions or organic anions. Common cations used in construction of ILs are 
unsymmetrically substituted nitrogen-containing cations or onium ions (e.g. 
imidazolium, pyridinium, pyrrolidinium, quaternary ammonium, quaternary 
phosphonium or quaternary sulfonium). Anions being constituted in ILs can be 
halogen ions, hexafluorophosphate, tetrafluoroborate or carboxylate (Scheme 
2.6).84 These ions are poorly coordinated, hence resulting in the solvents 
being liquid at room temperature. At least one ion has a delocalized charge 
and one component is organic, which prevents the formation of a stable crystal 
lattice (Figure 2.3).85  
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Scheme 2.6 Examples of cations and anions commonly found in ILs.84 
 Depending on their diverse combinations of cations and anions, ILs exhibit 
distinguishing physico-chemical properties, such as relatively low viscosity, 
negligible vapor pressure, non-flammability, high thermal and chemical 
stability.86 Significantly, ILs have good dissolubility for a wide range of polar,87 
non-polar compounds88 and biological macromolecules (e.g. peptides,89,90,91 
proteins,92 polysaccharides93,94 and nucleic acids95), as well. The miscibility of 
IL with water and organic solvents can be regulated with the lengths of side 
chains on the cation and with the type of anion.96,97 Thus, some ILs can be 
recovered from the waste and reused after extraction of the product with 
another solvent, which is not miscible with the respective IL.98 It is reported 
that Lewis base ILs can even be recycled by distillation in some cases.99 
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Figure 2.3 Comparison of the characters of ionic solid (crystallized salt) and ionic 
liquid (adaptation based on resource85). 
 Due to these impressive features, the applications of ILs as reaction media 
in numerous organic reactions have been explored, including 
hydrogenation, 100 hydroformylation, 101 oligomerization, 102 oxidation, 103
reduction, 104  ring opening, 105  Aldol condensation, 106 Beckmann 
rearrangement, 107  Diels-Alder, 108  Friedel-Crafts, 109  Stille, 110  Wittig, 111 
Heck112 and Suzuki reaction,113 and so forth. The ILs are not only used as 
solvents, but sometimes also act as precursor of an N-heterocyclic carbene,114 
Lewis acid115 or Lewis base99 in organic reactions. 
2.3.2 Application of ILs in peptide chemistry 
 As mentioned above, ILs have an outstanding ability to dissolve biological 
macromolecules. A recent study showed that ILs could be used as an effective 
solvent for increasing enzyme activity in enzyme-catalyzed reactions.116,117,118 
ILs have been found to reduce aggregation of proteins and to improve in vitro 
refolding. 119 , 120  The application of ILs in separation and purification of 
biomolecules has been also established.121122,123 These facts demonstrated 
that ILs became an inimitable solvent for biomolecules.  
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 The successful applications of ILs in biochemistry provide a potential 
solution for the solvent problem in the chemical synthesis of peptides. In 2004, 
the first report of dipeptide formation in neat ILs was published by 
Jean-Christophe Plaquevent and coworkers.124 After that, the coupling leading 
to various small peptides was carried out with the addition of distinct additives 
in an imidazolium-based IL.125 Weishi Miao et al. developed a new method 
called “IL-supported peptide synthesis” (ILSPS) for producing 
Leu(5)-enkephalin (a 5-mer endogenous opioid peptide), in which an 
imidazolium-based IL was used as loading support to replace the solid resin 
support of the conventional SPPS method (Scheme 2.7).126 In the ILSPS 
method, the loading capacity of ILSPS is much higher than in SPPS. As a 
previous work of our laboratory, tridegin (a 66mer anticoagulant peptide) was 
successfully synthesized by NCL using an imidazolium-based IL as reaction 
medium.36 It needs to be highlighted that the addition of additives has not been 
required during the NCL reaction here. Furthermore, the influences of different 
ILs on the oxidative folding yields of μ-SIIIA (a 20mer conotoxin peptide) have 
been also investigated previously.127 
 Besides the wide use in peptide synthesis, there are numerous 
applications of ILs in analytical chemistry, which have been recently 
summarized in a review written by Alesia A. Tietze et al..128 
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4  Results and Discussion 
4.1 Native Chemical Ligation (NCL) of peptides 
 In 1999, Hackeng T.M. and his co-workers 60 reported that the amino acid 
at the C-terminus of the peptide thioester fragment had a great impact on the 
yield of a conventional NCL reaction. They performed a series of NCL 
reactions between two unprotected model peptide fragments, namely the 
N-terminal thioester, which provided a thioester group at its C-terminus, and 
the C-terminal peptide bearing a cysteine residue at its N-terminus. In these 
reactions, the thiol group of the cysteine residue of fragment 
Cys-Arg-Ala-Asn-Lys-NH2 (referred to as CRANK) attacks the C-terminal 
thioester of fragment Leu-Tyr-Arg-Ala-Xaa-SR (LYRAX-thioester, Xaa = any 
amino acid) to form a native amide bond at the ligation site (Scheme 4.1). The 
desired product of the NCL reactions should be the decapeptide 
LYRAXCRANK (X = any amino acid). In the experiments of Hackeng et al., the 
NCL reactions of five LYRAX-peptides (X = pool 1, W, E, D, T, S; pool 2, R, Q, 
N, P, G; pool 3, F, M, I, V, A; or pool 4, Y, K, L, C, H) have been carried out 
simultaneously in one tube under 37 °C.60  
 Reaction rates and yields of the individual ligations have been 
demonstrated by MALDI analysis of the product formation over a time period of 
up to 72 hours.60 However, as Hackeng et al. annotated in their report,60 the 
MALDI analysis is not strictly quantitative for yield determination.  
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Scheme 4.1 (A) Thioester exchange reactions with benzyl mercaptan and thiophenol. 
(B) General mechanism of native chemical ligation exemplified for model peptide
LYRAXCRANK (X = any amino acid) (adaptation based on resource60).
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4.1.1 NCL in buffer system 
 The NCL reactions performed by Hackeng et al.60 were repeated herein in 
order to provide evidence of accomplished reaction to be compared with the 
same ligations performed in IL (see chapter 4.1.2). The peptide fragments 
LYRAG, LYRAA, LYRAL, LYRAF, LYRAN, LYRAQ, LYRAK and CRANK were 
selected as reactants89 according to the groups of peptides determined by 
Hackeng et al.:60 a) ligation of LYRAFCRANK completed within 4 hours, b) 
ligation of LYRAACRANK and LYRAGCRANK completed within 9 hours, c) 
ligation of LYRANCRANK, LYRAQCRANK and LYRAKCRANK completed 
within 24 hours, and finally d) ligation of LYRALCRANK completed within 48 
hours (Table 4.1).89 
Table 4.1 Peptide reactants and ligation products in NCL reactions. 
Peptide reactant Ligation product 
Abbrev. Sequence synthesized Abbrev. Sequence synthesized 
LYRAG Ac-LYRAG-SCH2CH2COOCH3 LYRAGCRANK Ac-LYRAGCRANK-NH2 
LYRAA Ac-LYRAA-SCH2CH2COOCH3 LYRAACRANK Ac-LYRAACRANK-NH2 
LYRAL Ac-LYRAL-SCH2CH2COOCH3 LYRALCRANK Ac-LYRALCRANK-NH2 
LYRAF Ac-LYRAF-SCH2CH2COOCH3 LYRAFCRANK Ac-LYRAFCRANK-NH2 
LYRAN Ac-LYRAN-SCH2CH2COOCH3 LYRANCRANK Ac-LYRANCRANK-NH2 
LYRAQ Ac-LYRAQ-SCH2CH2COOCH3 LYRAQCRANK Ac-LYRAQCRANK-NH2 
LYRAK Ac-LYRAK-SCH2CH2COOCH3 LYRAKCRANK Ac-LYRAKCRANK-NH2 
CRANK H-CRANK-NH2   
 
 In addition, a buffer system containing thioadditives was prepared as 
reaction medium. Each reaction was performed at room temperature (20 °C) 
instead of 37 °C used by Hackeng et al.60 and in an argon atmosphere. The 
reaction process was monitored by using high-performance liquid 
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chromatography (HPLC) analysis of the individual reactions in order to 
optimize the quantification.89 
 It was observed that the NCL reaction of product LYRAGCRANK was 
finished within 8 hours (Fig4.1A,C), and a ligation yield of 81% was obtained 
(Table 4.2). However, most of the ligation reactions were still not completed 
after 3 days. An example among them is the peptide ligation of fragment 
LYRAL to CRANK which proceeded with an extremely low conversion rate of 
fragment LYRAL (Fig4.1B,C). According to the experimental results, the 
C-terminal amino acid of the N-terminal fragment can be considered as an 
important influencing factor of the ligation rate. A similar finding was also 
reported by Hackeng et al. earlier. 60 
 In contrast, the NCL reaction was enhanced for glycine at the ligation site 
regardless of the reaction temperature (room temperature vs. 37°C) (Table 
4.2). In this work, leucine was found to be one of the most hindered amino 
acids for the NCL reaction at both temperatures (Table 4.2, Fig. 4.1B). 
Simultaneously, some differences were observed when comparing NCL at 
room temperature with NCL at 37 °C. The yields of all peptide ligations at room 
temperature, especially of peptides LYRAXCRANK with X = Ala, Phe, and Gln 
were obviously lower than the yields obtained at 37 °C. This phenomenon 
revealed that low temperature was generally unfavorable to the efficiency of 
the NCL reactions performed in buffer (Table 4.2). In addition, the continuous 
accumulation of the “activated” intermediates, e.g. peptide thioester with R = 
benzyl mercaptane-derived (LYRAL, LYRAK) or R = thiophenol-derived 
(LYRAQ) (Scheme 4.1-A), was determined by HPLC. The results 
demonstrated that the traditional thioadditives were not effective enough for 
the reverse transesterification for NCL with leucine, phenylalanine or glutamine 
at the ligation site. Thus, the amino acids at the ligation site can be ranked in 
order of the ligation yields in buffer system as follows: (high yield) G > K, A > L, 
N > Q > F (low yield) (Table 4.2). 
4 Results and Discussion 
31 
Figure 4.1 HPLC profiles of the ligation reactions obtained in buffer system60 for 
linking of (A) LYRAG to CRANK resulting in peptide LYRAGCRANK, (B) LYRAL to 
CRANK resulting in peptide LYRALCRANK, (C) Plot of yields vs. reaction time for the 
formation of peptides LYRAXCRANK (X = G, A, L, F, N, Q, and K) (adapted with 
permission from the author’s publication89). 
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4.1.2 NCL in [C2mim][OAc] 
 As mentioned in chapter 1, a series of imidazolium-based ILs has been 
screened already as potential reaction media for the preparation of 66mer 
peptide tridegin by NCL.36 Some of these imidazolium-based ILs showed an 
amazingly high capacity for dissolving the peptide reactants in higher 
concentrations (> 2 mM) as compared to aqueous buffer systems ( 
0.4 mM).36 This can be exemplified by the imidazolium-based ILs, which 
contained the following anions: para-toluenesulfonate ([OTs]−), 
diethylphosphate ([DEP]-), and dicyanamide ([N(CN)2]−). Interestingly, besides 
the outstanding dissolving capacity, the ILs 1-ethyl-3-methylimidazolium 
acetate ([C2mim][OAc]) and 1-butyl-3-methylimidazolium acetate 
([C4mim][OAc]) have been found to possess an enhancing effect on the 
ligation rate and yield. However, so far, the applicability of these ILs has not 
been verified for NCL reactions employing different C-terminal amino acids at 
the N-terminal fragment. Hence, the ligation reactions leading to model peptide 
LYRAXCRANK (X = any amino acid) were repeated in the Ionic Liquid 
[C2mim][OAc] and compared to the reactions in a buffer system (chapter 
4.1.1). 
 Neat [C2mim][OAc] was applied as reaction medium for the individual 
ligation reactions to form LYRAXCRANK with the same amino acids for X as 
used in chapter 4.1.1: G, A, L, F, N, Q, K). In addition, no additives (e.g. 
benzylmercaptan, thiophenol or MPAA) were added during the reaction 
process. All other conditions were the same as for the reactions performed in 
buffer system. 
The reactions were monitored by HPLC. The results showed that almost 
all the reactions performed in [C2mim][OAc] reached their maximum yield 
much faster than comparable NCL reactions in buffer (Table 4.2, Figure 4.2). 
All the reactions were finished (100% conversion of LYRAX) in 2 hours. In 
contrast to the ligation yields obtained in buffer system, the yields of most NCL 
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reactions were significantly increased in IL even though the reactions were 
carried out without any additives (Table 4.2, Figure 4.2). 
 However, in [C2mim][OAc], the C-terminal amino acid at ligation site (X) of 
product LYRAXCRANK was also observed to have an impact on the reaction 
yields. Compared to the yield (57%) in an aqueous medium, the reaction with 
X = glycine performed in the IL was still the fastest and gained the highest yield 
(98%) within the first hour (Table 4.2, Figure 4.1-A, Figure 4.2-A). The reaction 
with X = leucine, formerly determined as “a sluggish residue” for NCL60, has 
reached a relatively high yield of 36% in 2 hours, compared to the yield (19%) 
at room temperature after 24 h (Table 4.2, Figure 4.1-B, Figure 4.2-B). 
Interestingly, phenylalanine, which was the second most hindered amino acid 
in buffer system, has reacted at almost the same reaction rate and yield as 
glycine in [C2mim][OAc]. 
 However, the yields of the products in [C2mim][OAc] were found to be 
gradually decreased after 1-2 hours (Fig. 4.2-C). Obviously, higher 
concentrations of product led to the formation of different byproducts 
preferably by reacting with the IL ions. The formation of several byproducts 
was detected in HPLC elution profiles and confirmed by mass spectrometry. 
For some peptides, a byproduct was observed which linked product 
LYRAXCRANK to the excess reactant CRANK (X = G, F, K) or 
methyl-3-mercaptopropionate (X = G, A, N, Q) by forming a disulfide bridge 
(Scheme 4.2). The molecular mass, which represented a LYRAXCRANK 
molecule connected via a thioether bridge to methyl-3-mercaptopropionate, 
had also been detected in the ligation of LYRALRANK and LYRAQRANK 
(Scheme 4.2). In particular, it was also found that the peptide reactants LYRAN 
and LYRAQ were converted to a special byproduct, i.e. a cyclic imide, in 
[C2mim][OAc]. A possible reason for this finding was suggested to be a side 
reaction called deamidation, in which the -amino group of asparagine or 
glutamine attacks its own backbone carbonyl to form a cyclic imide (Scheme 
4 Results and Discussion 
34 
4.2). This side reaction occurring during the preparation of peptides and 
proteins was described several times in earlier reports.129,130,131
Table 4.2 Comparison of the conversion rates and the ligation yields obtained in 
different reaction media (adaptation based on resource89).  
Ligation 
product 
Conversiona Reaction yields (reaction time) 
Buffer, 37 °C60 Bufferb, RT ILc, RT 
LYRAGCRANK ~100% 
(after  4 h) 57% (1 h) 
81% (8 h) 
85% (10 min) 
98% (1 h) 
83% (2 h)d 
LYRAACRANK ~100% 
(after  9 h) 8% (1 h) 
43% (24 h) 
49% (10 min) 
84% (1 h) 
78% (4 h)d 
LYRALCRANK ~100%  
(after  48 h) 
25% (8 h) 
19% (24 h) 
27% (10 min) 
36% (1 h) 
20% (8 h)d
LYRAFCRANK ~100% 
(after  9 h) 0% (1 h) 
3% (48 h) 
29% (10 min) 
83% (1 h) 
78% (8 h)d 
LYRANCRANK ~100%  
(after  24 h) 
5% (1 h) 
16% (8 h) 
-e,f 
LYRAQCRANK ~100%  
(after  24 h) 
3% (1 h) 
11% (24 h) 
11% (1 h)e 
45% (24 h) 
LYRAKCRANK ~100%  
(after  24 h) 
4% (1 h) 
41% (24 h) 
29% (1 h)f 
10% (24 h)d,f 
a Values are estimated from MALDI analysis reported in reference60. 
b Buffer conditions: 0.1 M phosphate buffer (pH 8.5) containing 6 M guanidinium 
chloride, 4% (vol/vol) benzyl mercaptan and 4% (vol/vol) thiophenol. 
c IL: [C2mim][OAc]. For evaluation, the amount of the LYRAXCRANK-product as well 
as the IL-oxidized product were combined. 
d Side product formation in IL led to reduced product formation. 
e LYRAX-thioester in this approach immediately degraded. 
f Product formation could not or only partially be determined due to a peak-overlay of 
side product and product in the chromatogram 
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Yamanouchi Pharmaceuticals in 2003.133 This specific Gq/11 inhibitor may 
help us to understand the role of Gq/11 in GPCR transactivation signaling. 
Various studies have shown that YM-254890 could be a potential 
anti-hypertensive agent, besides its antithrombotic and thrombolytic effects.136  
 However, this compound cannot be obtained commercially from 
Yamanouchi Pharmaceuticals (Fujisawa Pharmaceuticals) anymore. 137  In 
addition, no successful synthesis of YM-254890 has been reported so far, 
even though a $100,000 USD award has been offered for this challenge on 
the global innovation market since 2012.138 
 Due to the difficulty and complexity of depsipeptide syntheses, several 
attempts have been undertaken recently to produce analogues of 
YM-254890.138  The structure-activity relationship of YM-254890 (Scheme 
4.3-B) and its analogues YM-254891 and YM-254892 (Scheme 4.3-C) 
indicated that the acyl--hydroxyleucine residue is a crucial group to the 
inhibitory activity while the ,-unsaturated carbonyl group of the N-MeDha 
(Dha = dehydro-alanine) residue is not important.139 Furthermore, Rensing et 
al. have designed an analogue of YM-254890 as a potential Gq inhibitor, 
namely WU-07047 (Scheme 4.3-E). 140  In order to enable a convergent 
approach to the synthesis, the two peptide-based linkers in the cyclic 
YM-254890 have been replaced with hydrocarbon chains in the analogue. 
YM-280193 (Scheme 4.3-D),139 another analogue of YM-254890, was 
synthesized by Brimble et al. recently.138 Unfortunately, neither of these 
peptides, YM-280193 (Scheme 4.3-D) and WU-07047 (Scheme 4.3-E) have 
been determined as potent Gq/11 inhibitor compared to YM-254890. 
 Since YM-254890 is not available currently, effort has been made to 
simplify the natural structure of the compound by marginal modifications, so 
that multitudinous analogues could be obtained easily by SPPS method. Such 
modifications should reduce the complexity of synthetic strategies 
conspicuously compared to the solution-phase approaches described so far. 
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This molecular design work was based on a combination of our chemical 
experience and structural investigations in collaboration with Dr. Daniel Tietze 
(TU Darmstadt), who performed additional molecular modelling and docking 
studies (Table 4.3). In the first peptide modification, the dehydroalanine 
residue, the -hydroxyleucine residue and the ester bond have been replaced 
by an alanine, a leucine and a peptide bond, respectively (Scheme 4.3-F, 
abbreviated as YM-1). However, the unsuccessful synthesis of this analogue 
still bearing an ester bond impelled us to continue with simplification of 
backbone and side chain modifications. Unfortunately, a complete coupling 
failure was still encountered at the O-methyl-L-threonine in the second 
analogue intended (Scheme 4.3-F, abbreviated as YM-2). This problem has 
been solved by substituting the methyl group for the use of acetyl-L-threonine. 
Thus, a series of cyclic analogues as shown in Table 4.4 and Scheme 4.3-G 
(abbreviated as YM3–YM10) has been designed and prepared. 
 Before the cyclization, the linear precursor peptides needed to be 
synthesized by SPPS (Scheme 4.4). The linear peptides of YM3–YM10 (Table 
4.4) were synthesized on 2-chlorotrityl chloride resin (loading: 2.1 mmol/g) or 
2-alanine-chlorotrityl chloride resin (loading: 0.67 mmol/g). All subsequent 
amino acids were coupled by using stepwise Fmoc-based SPPS. After 
deprotection and cleavage from the solid support using a mixture of reagent K 
and trifluoroacetic acid (TFA), the crude linear peptides were precipitated in 
cold diethyl ether. After purification and freeze-drying, the pure linear peptides 
were stored at -20 °C before the cyclization step. 
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Table 4.3 Binding parameters obtained from docking studies performed on 
YM-analogues YM-3 and YM-4 (kindly provided by Dr. Daniel Tietze, TU Darmstadt) 
Peptide Binding Energy (kcal/mol) Inhibitory Constant Ki (μM) 
YM-254890 9.85 0.06 
YM-3 9.20 0.18 
YM-4 8.94 0.28 
 
Table 4.4 Peptide sequences of cyclic analogues of YM-254890. 
Peptide 
Abbr. 
Sequencea 
Expected 
mass 
[M+H]+ 
Measured 
massb 
[M+H]+ 
YM-3 cyclo[Ala-NMeAla-Lys(Ac)-Thr(OMe)-Thr(OMe)-D-Phe-NMeAla] 788.5 789.44 
YM-4 cyclo[Ala-NMeAla-Lys(Ac)-Thr(OMe)-Thr(OMe)-Phe-NMeAla] 788.5 789.44 
YM-5 cyclo[Ala-Ala-Lys(Ac)-Thr(OMe)-Thr(OMe)-D-Phe-Ala] 760.4 761.44 
YM-6 cyclo[Ala-Ala-Lys(Ac)-Thr(OMe)-Thr(OMe)-Phe-Ala] 760.4 761.44 
YM-7 cyclo[Ala-NMeAla-Leu-Thr(OMe)-Thr(OMe)-D-Phe-NMeAla] 731.4 732.42 
YM-8 cyclo[Ala-NMeAla-Leu-Thr(OMe)-Thr(OMe)-Phe-NMeAla] 731.4 732.42 
YM-9 cyclo[Ala-Ala-Leu-Thr(OMe)-Thr(OMe)-D-Phe-Ala] 703.4 704.42 
YM-10 cyclo[Ala-Ala-Leu-Thr(OMe)-Thr(OMe)-Phe-Ala] 703.4 704.39  
a All peptides were cyclized using via lactam bridge between the N- and the C-terminal.  
b If the peptide was detected in a higher charged state, [M+H]+ was calculated from this peak. 
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Scheme 4.4 Synthetic strategy for cyclic peptides exemplified for YM-3. 
 As described in earlier publications, the linear precursors can be 
successfully cyclized by using PyBOP as coupling reagent and 
N,N-diisopropylethylamine (DIEA) as the base (Scheme 4.4).141,142,143,144 
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4.2.2 Peptide cyclization in an organic solvent 
 Hereafter, the linear peptides of YM-3–YM-10 were cyclized manually 
using the coupling reagent PyBOP and the organic base DIEA in the organic 
solvent N,N-dimethylformamide (DMF) for 6 hours at room temperature to 
form the cyclic products (Scheme 4.4).  Argon gas atmosphere was not 
necessary here because no sensitive residue existed in the sequences. All the 
linear and cyclic peptides in this experiment were purified by reversed-phase 
HPLC, and the mass was confirmed by electrospray ionization (ESI) mass 
spectrometry.  
 For the reactions performed in DMF, the yields of all cyclic peptides YM-3–
YM-10 have been determined to reach their maximum values in the first 15-30 
minutes and remained substantially stable in the next hours (Figure 4.3-C). 
The final yields were obtained after 6 hours reaction time for YM-5, YM-7, 
YM-8, and YM-9, which reached up to 70 - 80%, while the yields for YM-3, 
YM-4, YM-6, and YM-10 (approx. 50 - 60%) were lower, yet seemed to be fair 
as well (Figure 4.3A, B). This study revealed that the reaction time suggested 
from other protocols for cyclization141,142,143,144 can be shortened at least for 
the peptides described herein and similar analogues. 
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Figure 4.3 HPLC profiles of the cyclization reactions obtained in DMF of (A) YM-4, 
and (B) YM-6; (C) Plot of yields vs. reaction time for the cyclization of peptides YM-3–
YM-10. 
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4.2.3 Peptide cyclization in [C4mim][PF6] 
 Considering the high content of hydrophobic residues in the peptide 
sequences described herein, such as Phe, Leu and NMeAla, a lot of efforts 
have been made to optimize the reaction media. So far, the primarily used 
organic solvent for peptide cyclizations, both in solution and on the solid phase, 
is DMF.141,142,143,144 In addition, others such as acetonitrile, 145  dimethyl 
sulfoxide (DMSO)146 and isopropanol147 were applied as well. In our previous 
work, ionic liquids have been applied for the synthesis of peptides, such as the 
66mer peptide tridegin.36 In addition, disulfide bond formation occurred very 
efficiently in the imidazolium-based IL 1-ethyl-3-methylimidazolium acetate 
([C2mim][OAc])148, and Heimer et al. also performed the oxidative folding of 
the µ-conotoxin SIIIA in different ILs under up-scaled conditions.127 However, 
no report about the head-to-tail cyclization of peptides in ILs was described so 
far. Thus, our interest concerning peptide chemistry performed in ILs led us to 
investigate the applicability of these new media in the preparation process of 
the cyclic peptides YM3–YM10 (Table 4.4). 
 PyBOP was again selected as coupling reagent for reasons of comparison 
and since it was already successfully used earlier in our laboratory. However, 
it has been observed that the PyBOP was not long-term stable in both ILs 
[C2mim][N(CN)2]− and [C2mim][OAc], even though [C2mim][OAc] has been 
successfully used in peptide ligation reactions. Thus, the IL 
1-butyl-3-methylimidazolium hexafluorophosphate ([C4mim][PF6]), which has
been used by J.-C. Plaquevent et al. for dipeptide formation, was applied as
reaction medium.124 J.-C. Plaquevent and coworkers reported that
[C4mim][PF6] enhanced the peptide coupling reactions for the generation of
dipeptide Boc-2-methyl-2-(p-tolyl)-glycine-glycine-methyl ester, and the
purities of crude products were higher than the couplings carried out in a
classical solvent, e.g. dichloromethane (DCM). 124
One equiv. of linear peptide (YM3–YM10) and 6 equiv. of PyBOP were first 
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dissolved in 2000 equiv. of [C4mim[]PF6]. Then, 12 equiv. of the organic base 
DIEA was added. All the experiments were performed under room 
temperature and continuous stirring (Scheme 4.5). The formation of cyclic 
products (YM3–YM10) was monitored by HPLC analysis over a time period of 
up to 6 hours. Simultaneously, in order to verify the efficiency of ILs, these 
cyclization reactions were also carried out in DMF instead of [C4mim][PF6] 
under the same conditions. 
Scheme 4.5 Synthetic strategy for cyclization reaction of YM-254890 analogue YM-3 
of in [C4mim][PF6]. 
In contrast to the results obtained in DMF, the reaction rates and yields of 
the products formed in [C4mim][PF6] were found to be significantly different 
(Figure 4.4). The cyclization reactions of the peptides containing an acetylated 
lysine residue, including YM-3, YM-4, YM-5, and YM-6 were rather slow within 
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the first 2 hours and achieved a relative high yield (>60%) after 6 hours 
reaction time. The cyclic peptides YM-9 and YM-10 were formed with yields of 
61% and 51%, respectively, which were somewhat lower than the yields of 
YM-9 (78%) and YM-10 (56%) in DMF, but still acceptable. 
 However, it has been determined that the yields of the cyclic products 
YM-7 (42%) and YM-8 (33%) in IL were only half of those in DMF (85% and 
88%, respectively). It was also observed that the yield of YM-7 in IL was 
gradually decreased from 62% (30 min) to 42% (6 hours) after 30 minutes, 
even though it was increasing dramatically in the first 30 min. Compared to the 
results in DMF, all the cyclic peptides containing leucine were formed with 
relatively low yields. 
Table 4.5 Cyclization yields of the peptide analogues formed in the Ionic Liquid. 
Peptide 
Abbr. 
Yielda 
DMF / reaction time [C4mim][PF6] / reaction time 
15 min 2 hrs 6 hrs 15 min 2 hrs 6 hrs 
YM-3 55% 62% 58% 36% 64% 65% 
YM-4 48% 51% 54% 16% 60% 65% 
YM-5 72% 80% 81% 11% 66% 67% 
YM-6 57% 63% 63% 47% 74% 67% 
YM-7 89% 78% 85% 58% 52% 42% 
YM-8 77% 83% 88% 29% 31% 33% 
YM-9 77% 76% 78% 34% 57% 61% 
YM-10 52% 56% 56% 5% 49% 51% 
a Yields were determined by HPLC analysis. 
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Figure 4.4 HPLC profiles of the cyclization reactions obtained in [C4mim][PF6] of (A) 
YM-4, and (B) YM-6; (C) Plot of yields vs. reaction time for the cyclization of peptides 
YM-3–YM-10. 
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4.2.4 Pros and Cons of IL application for peptide cyclization in solution 
 According to the experimental results, [C4mim][PF6] might be used as an 
alternative reaction medium for the cyclization reaction examined in this work. 
It was found that the residue leucine could be considered as a hindered 
residue for the cyclization yields of the peptides studied. To a certain extent, 
[C4mim][PF6] as a hydrophobic solvent could be a suitable solvent to 
synthesize the polar cyclic peptides (e.g. YM-3, YM-4) rather than the most 
non-polar ones (e.g. YM-7, YM-8). Furthermore, it was also demonstrated that 
the coupling reagent PyBOP could work efficiently even in a Brønsted acidic 
ionic liquid, i.e. [C4mim][PF6]. 
 On the other hand, the interactions between ILs, additives or peptides 
during the cyclization were still unclear. It has been observed that the reaction 
rates have been slightly reduced over time if using [C4mim][PF6] in contrast to 
DMF.  
 A possible reason for these facts may be the strong interactions between 
the peptide’s backbone/amino acid side chains and ionic liquid cations and 
anions, since P. Heimer et al.127 observed that the anion from IL contacted 
preferentially the lysine residue in both folded and unfolded toxin peptide 
μ-SIIIA.  
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2 hours.149 After washing with dry THF methylated resin was incubated with 
methyl-3-mercaptopropionate (280 equiv.) and sodium thiophenoxide (2.8 
equiv.) for 24 hours under gentle agitation.150 The resulting peptide solution 
was filtrated, washed 3-times with DMF and evaporated to dryness on a rotary 
evaporator. The product was triturated with diethyl ether, and the residue was 
treated with TFA:water:triisopropylsilane:phenol (88:5:2:5) for 2 hours at room 
temperature. The cleavage solution was precipitated in diethyl ether, 
centrifuged and washed several times with diethyl ether. The yields of the 
crude peptides ranged between 10–40% for LYRAX-thioesters and 70–80% 
for CRANK and LYRAXCRANK peptides (X = G, A, L, F, N, Q, K). After 
lyophilisation, the remaining solid was purified using HPLC. 
 The purification of the crude peptides was performed by semipreparative 
reversed-phase HPLC using a Shimadzu LC-8A system equipped with a C18 
column (Knauer Eurospher 100, 32 x 250 mm, 5 µm particle size, 100 Å pore 
size, Berlin, Germany). The gradient elution system was 0.1% TFA in water 
(eluent A) and 0.1% TFA in acetonitrile/water (9:1) (eluent B). The peaks were 
detected at 220 nm. The flow rate used was 10 ml/min. Purity of the peptides 
was confirmed by thin layer chromatography (Table 5.1) and analytical 
reversed-phase HPLC on a Shimadzu LC-10AT chromatograph with a Vydac 
218TP column (4.6 x 250 mm, 5 µm particle size, 300 Å pore size) and a 
mobile phase system consisting of A: 0.1% TFA in water and B: 0.1% TFA in 
acetonitrile. The detection was at 220 nm. Detailed information on chemical 
characterization of the selected peptides has been summarized in Table 5.1. 
The pure peptides were lyophilized and stored at −20 °C until use.  
 The determination of molar mass was performed with MALDI-TOF mass 
spectrometry on an Autoflex TOF/TOF mass spectrometer (Bruker Daltonics) 
with α-cyano-4-hydroxycinnamic acid as matrix. 
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Figure 5.1 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products obtained in buffer system of reacting LYRAG with CRANK 
resulting in LYRAGCRANK (reprinted with permission from the author’s publication89). 
Figure 5.2 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products obtained in buffer system of linking LYRAA with CRANK resulting 
in LYRAACRANK (reprinted with permission from the author’s publication89). 
A B 
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Figure 5.3 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in buffer system of 
reacting LYRAL with CRANK resulting in LYRALCRANK (reprinted with permission 
from the author’s publication89). 
A 
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Figure 5.4 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in buffer system of 
reacting LYRAF with CRANK resulting in LYRAFCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.5 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in buffer system of 
reacting LYRAN with CRANK resulting in LYRANCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.6 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in buffer system of 
reacting LYRAQ with CRANK resulting in LYRAQCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.7 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in buffer system of 
reacting LYRAK with CRANK resulting in LYRAKCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.8 HPLC profiles of the incubation of control peptides LYRAXCRANK (X=G, 
L, F, N) in [C2mim][OAc] displaying a shift of the retention time during incubation due 
to oxidation processes (reprinted with permission from the author’s publication89). 
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Figure 5.9 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in [C2mim][OAc] for 
reacting LYRAG with CRANK resulting in LYRAGCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.10 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in [C2mim][OAc] of 
reacting LYRAA with CRANK resulting in LYRAACRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.11 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in [C2mim][OAc] of 
reacting LYRAL with CRANK resulting in LYRALCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.12 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in [C2mim][OAc] of 
reacting LYRAF with CRANK resulting in LYRAFCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.13 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in [C2mim][OAc] of 
reacting LYRAN with CRANK resulting in LYRANCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.14 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in [C2mim][OAc] of 
reacting LYRAQ with CRANK resulting in LYRAQCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.15 HPLC profiles (A) of the ligation reactions and mass spectra (B) of the 
observed products and intermediates/byproducts obtained in [C2mim][OAc] of 
reacting LYRAK with CRANK resulting in LYRAKCRANK (reprinted with permission 
from the author’s publication89). 
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Figure 5.16 HPLC profiles of the ligation reactions obtained in [C2mim][OAc] of 
reacting LYRAL with CRANK at different ratios (1:2, 1:1, 2:1) resulting in peptide 
LYRALCRANK after 4 hours (A) and 8 hours (B) (reprinted with permission from the 
author’s publication89). 
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Figure 5.17 HPLC profiles of the ligation reactions obtained in [C2mim][OAc] of 
reacting LYRAK with CRANK at different ratios (1:2, 1:1, 2:1) resulting in peptide 
LYRAKCRANK after 4 hours (A) and 8 hours (B) (reprinted with permission from the 
author’s publication89). 
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5.5 Peptide cyclization via lactam bridge formation 
5.5.1 Peptide cyclization in DMF 
 Peptide cyclization was performed in DMF with a final peptide 
concentration of 0.65 mM and 6 equiv. PyBOP. The reactions were started by 
adding DIEA (12 equiv.). The mixture was stirred continuously at room 
temperature for 6 hours. Progress of the reaction was monitored by analytical 
reversed-phase HPLC on a Jasco LC-Net II/ADC chromatograph equipped 
with a Vydac 218TP column (4.6 x 25 mm, 5 µm particle size, 300 Å pore size) 
and a mobile phase system consisting of A: 0.1% TFA in water and B: 0.1% 
TFA in acetonitrile. The detection was at 220 nm. Samples for monitoring of 
cyclization reactions were diluted with a quenching solution (acetonitrile:water, 
45:55)125 in a ratio of 1:16. For each analysis, a continuously increasing 
gradient was applied starting at 0% eluent B and finishing at 50 % eluent B in 
50 min. The flow rate used was 1 ml/min. Single peaks were collected, 
freeze-dried and forwarded to mass spectrometry analysis. 
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Figure 5.18 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-3 in DMF. 
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Figure 5.19 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-4 in DMF. 
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Figure 5.20 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-5 in DMF. 
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Figure 5.21 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-6 in DMF. 
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Figure 5.22 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-7 in DMF. 
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Figure 5.23 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-8 in DMF. 
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Figure 5.24 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-9 in DMF. 
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Figure 5.25 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-10 in DMF. 
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5.5.2 Peptide cyclization in [C4mim][PF6] 
 One equivalent of peptide and 6 equiv. of PyBOP were dissolved into 2000 
equiv. of pure [C4mim][PF6] (≤0.02% water content). The reactions were 
started by adding DIEA (12 equiv.). The mixture was stirred continuously at 
room temperature for 6 hours. Progress of the reaction was monitored by 
analytical reversed-phase HPLC on a Jasco LC-Net II/ADC chromatograph 
equipped with a Vydac 218TP column (4.6 x 25 mm, 5 µm particle size, 300 Å 
pore size) and a mobile phase system consisting of eluent A (0.1% TFA in 
water) and eluent B (0.1% TFA in acetonitrile). Samples for monitoring of 
cyclization reactions performed in IL were diluted with a quenching solution 
(acetonitrile:water, 45:55)125 in a ratio of 1:16. The detection was at 220 nm. 
For each analysis, a continuously increasing gradient was applied starting at 0% 
eluent B and finishing at 50 % eluent B in 50 min. The flow rate used was 1 
ml/min. Single peaks were collected, freeze-dried and forwarded to mass 
spectrometry analysis. 
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Figure 5.26 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-3 in the [C4mim][PF6]. 
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Figure 5.27 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-4 in [C4mim][PF6]. 
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Figure 5.28 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-5 in [C4mim][PF6]. 
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Figure 5.29 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-6 in [C4mim][PF6]. 
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Figure 5.30 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-7 in [C4mim][PF6]. 
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Figure 5.31 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-8 in [C4mim][PF6]. 
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Figure 5.32 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-9 in [C4mim][ PF6]. 
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Figure 5.33 HPLC profiles (A) and mass spectra (B) obtained from the cyclization 
reaction of peptide YM-10 in [C4mim][PF6]. 
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6  Summary 
 The application of ionic liquids in peptide chemistry has just started its 
exploration phase. So far, only few small peptides were synthesized by using 
ILs. In addition, only selected reactions, including amino acid condensation to 
simple dipeptides in solution and oxidative folding of cysteine-rich peptides, 
were studied. However, for confirming the applicability and compatibility of ILs 
for specific synthetic approaches in peptide chemistry, a systematic study is 
indispensable. Thus, in this thesis the focus regarding ILs in the process of 
peptide synthesis was laid on two distinct reaction types: first, native chemical 
ligation (NCL) for the generation of linear peptides by combining two 
fragments and second, lactam bridge formation for the production of cyclic 
peptides. 
 In case of NCL, the impact of the amino acid at the C-terminus of the 
N-terminal peptide thioester (fragment 1) on the efficiency of the ligation 
reaction was investigated in a conventional buffer system as well as in an IL. 
Seven NCL reactions with different C-terminal amino acid at fragment 1 were 
carried out in the neat IL [C2mim][OAc], which was previously shown to be 
beneficial for dissolving hydrophobic peptides. The results revealed that yields 
and rates of most NCL reactions were increased significantly compared to the 
ligation in the buffer system. Among them, C-terminal glycine residue was the 
least hindered amino acid at ligation site in both buffer system and IL. The 
phenylalanine residue, which caused the slowest reaction rate in buffer 
system, has been found to facilitate ligation in IL at a similar reaction rate as 
glycine. 
 Apart from the fact that the reaction time can be significantly reduced 
compared to the conventional method, the addition of additive is not required 
anymore if performed in [C2mim][OAc]. These observations shed light on a 
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further reaction type which can be performed successfully in an Ionic Liquid 
and simultaneously provide a protocol of reduced effort, costs of materials and 
reaction time. 
 In the second part of this thesis, the head-to-tail cyclization of peptides 
established via lactam bridge formation was examined in more detail. Thus far, 
the application of ILs on this reaction type was also not described before. 
Herein, a series of small linear peptides, designed as Gq inhibitors related to 
the natural depsipeptide YM-254890, was cyclized by using [C4mim][PF6] as 
solvent. The reaction was accomplished by using the coupling reagent PyBOP 
and DIEA as a base commonly used for peptide cyclization in solution. In most 
cases comparable or even higher yields were obtained for the peptides YM-3, 
YM-4, YM-5, YM-6, YM-9, YM-10 studied in comparison to the results 
obtained in DMF. However, an exception was found for the most nonpolar 
peptides YM-7 and YM-8, for which the yields were evidently lower compared 
to the conventional approach in DMF. Nevertheless, these first results prove 
the general applicability of an IL for another type of reaction involving peptide 
sequences, i.e. the macrocyclization of peptides via head-to-tail cyclization. 
 Taken together, this work has deepened the understanding of the use of 
ILs in peptide synthesis and thus expanded the possible applications. Ionic 
Liquids, as an attractive reaction medium, represent an outstanding solubility 
opportunity for peptides and reagents used in peptide synthesis. It could be 
highlighted that ILs had a beneficial effect on ligation reactions of peptide 
fragments, resulting in a clean and simple reaction. The compatibility of 
ligation strategy in IL for X–Cys ligation sites has been also clarified, which 
has a great value for synthetic approaches for peptides. Furthermore, this 
work has showed the first example of the head-to-tail cyclization of peptides in 
an IL. The applicability of ILs for lactam-bridge formation has thus been 
proved. However, the association of IL ions to the peptide sequence needs to 
be solved, since they could interfere with biological activity. 
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